Core Viewpoint - The Gross Law Firm is notifying shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy and overstated its clinical and commercial prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially be appointed as lead plaintiff [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy, overstating its clinical and commercial prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - ESSA Pharma Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2]. - The M-E Combination Study, which was intended to evaluate the treatment's effectiveness, is claimed to be unlikely to meet its primary endpoint as specified in Phase 2 [2]. - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 12, 2023, to October 31, 2024 [3]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy and overstated its clinical and commercial prospects [3]. Allegations Against ESSA Pharma Inc. - The complaint claims that masofaniten in combination with enzalutamide showed no clear efficacy benefit over enzalutamide alone [3]. - It is alleged that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint [3]. - The defendants are accused of misleading investors about the treatment's effectiveness for prostate cancer [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2] - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was reportedly unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [2] - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, defendants made materially false and misleading statements about masofaniten's efficacy [1]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone [1]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' public statements [1]. - Defendants allegedly overstated masofaniten's clinical, regulatory, and commercial prospects, leading to inflated stock prices [1]. Next Steps for Shareholders - Shareholders who purchased shares of EPIX during the specified timeframe are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - ESSA Pharma Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug masofaniten in combination with enzalutamide for prostate cancer treatment [3]. Group 1: Class Action Details - The class action represents investors who purchased ESSA Pharma securities between December 12, 2023, and October 31, 2024 [1]. - Investors have until March 25, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against ESSA Pharma - The complaint claims that ESSA Pharma made materially false and misleading statements about masofaniten's effectiveness when combined with enzalutamide, indicating no clear efficacy advantage over enzalutamide alone [3]. - The M-E Combination Study, which assessed masofaniten's performance, is unlikely to meet its primary endpoint as specified in Phase 2 [3]. - The company allegedly overstated masofaniten's clinical, regulatory, and commercial potential, leading to misleading public statements throughout the class period [3].

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Lawsuit Details - The complaint claims that ESSA Pharma Inc. made false statements regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the company's public statements about masofaniten's prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2]. - The M-E Combination Study, which was intended to evaluate the treatment's effectiveness, is said to be unlikely to meet its Phase 2 primary endpoint as previously stated [2]. - The defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/essa-pharma- ...